↓ Skip to main content

The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease

Overview of attention for article published in Frontiers in Aging Neuroscience, April 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
8 news outlets
blogs
1 blog
twitter
11 X users
facebook
1 Facebook page
wikipedia
1 Wikipedia page
reddit
1 Redditor
video
3 YouTube creators

Citations

dimensions_citation
240 Dimensions

Readers on

mendeley
528 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
Published in
Frontiers in Aging Neuroscience, April 2018
DOI 10.3389/fnagi.2018.00118
Pubmed ID
Authors

Holly M. Brothers, Maya L. Gosztyla, Stephen R. Robinson

Abstract

Amyloid-ß (Aß) is best known as the misfolded peptide that is involved in the pathogenesis of Alzheimer's disease (AD), and it is currently the primary therapeutic target in attempts to arrest the course of this disease. This notoriety has overshadowed evidence that Aß serves several important physiological functions. Aß is present throughout the lifespan, it has been found in all vertebrates examined thus far, and its molecular sequence shows a high degree of conservation. These features are typical of a factor that contributes significantly to biological fitness, and this suggestion has been supported by evidence of functions that are beneficial for the brain. The putative roles of Aß include protecting the body from infections, repairing leaks in the blood-brain barrier, promoting recovery from injury, and regulating synaptic function. Evidence for these beneficial roles comes from in vitro and in vivo studies, which have shown that the cellular production of Aß rapidly increases in response to a physiological challenge and often diminishes upon recovery. These roles are further supported by the adverse outcomes of clinical trials that have attempted to deplete Aß in order to treat AD. We suggest that anti-Aß therapies will produce fewer adverse effects if the known triggers of Aß deposition (e.g., pathogens, hypertension, and diabetes) are addressed first.

X Demographics

X Demographics

The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 528 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 528 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 86 16%
Student > Ph. D. Student 78 15%
Student > Master 55 10%
Researcher 54 10%
Other 19 4%
Other 58 11%
Unknown 178 34%
Readers by discipline Count As %
Neuroscience 80 15%
Biochemistry, Genetics and Molecular Biology 79 15%
Medicine and Dentistry 42 8%
Agricultural and Biological Sciences 39 7%
Chemistry 21 4%
Other 70 13%
Unknown 197 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 74. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 October 2023.
All research outputs
#590,324
of 25,711,518 outputs
Outputs from Frontiers in Aging Neuroscience
#127
of 5,559 outputs
Outputs of similar age
#13,116
of 340,687 outputs
Outputs of similar age from Frontiers in Aging Neuroscience
#6
of 113 outputs
Altmetric has tracked 25,711,518 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,559 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,687 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 113 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.